Answers are grounded in this paper and cite their sources.
Hairy-cell leukemia, a rare B-cell cancer driven by a BRAF mutation and manifesting with cytopenias and splenomegaly, is responsive to purine analogue chemotherapy and to BRAF inhibitors combined with anti-CD20 antibodies.
No takes yet. Share an insight, caveat, or question.
Falini et al. (2024) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: